Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 75

Biosimilars Pharmacy Marketing Drugs 75

Drug Channels

MARCH 28, 2023

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Production Drugs Marketing 98

Drug Channels

OCTOBER 31, 2023

It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. CVS Health frightens all but one Humira biosimilar maker away from its formulary. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Production Drugs 52

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Steve’s insights.

Biosimilars 98

Biosimilars Pharma Companies Marketing Research 98

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Marketing Drugs 98

Drug Channels

MARCH 30, 2023

So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

SEPTEMBER 13, 2022

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

AUGUST 23, 2022

Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline: Howard Dean attacks patient-unfriendly cost shifting Cancer patients’ views of copay assistance My $0.02 Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Specialty Pharmacies Pharmacy Drugs 98

Drug Channels

DECEMBER 12, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Pharmacy Hospitals Marketing 98

Drug Channels

APRIL 25, 2023

While we wait for the Phillies turnaround, let’s oil up our gloves, lace up our cleats, and run the bases around this month's biggest hits: Foul ball : OptumRx prefers higher prices for the first Humira biosimilar Strikeout : Copay accumulators hurt health equity Bench warmer : Surprise? d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars Drugs Pharmacy 75

Drug Channels

FEBRUARY 28, 2023

I am pleased to report that this month’s Drug Channels news roundup was most definitely not written by ChatGPT. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. No promises about future articles.

Biosimilars 97

Biosimilars Drugs 97

Drug Channels

MAY 30, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Summer unofficially began over the weekend. to 1:30 p.m. Click here to learn more and sign up. This Feed is for personal non-commercial use only.

Biosimilars 98

Biosimilars Hospitals Pharmacy Drugs 98

Drug Channels

JUNE 25, 2024

Join my nearly 57,000 LinkedIn followers for daily links to neat stuff along with commentary from the Drug Channels community. Note that we will soon migrate our social media activity to the Drug Channels Institute LinkedIn page. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars 52

Biosimilars Drugs Pharmacy 52

Drug Channels

OCTOBER 25, 2022

Time for my Halloween roundup of wicked Drug Channels’ tales. Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Drugs Pharmacy 98

Drug Channels

APRIL 29, 2024

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

APRIL 19, 2022

An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars. Anyone want to tell him about the Express Scripts formulary for insulin biosimilars? drug channel will limit the impact of this impressive breakthrough.

Biosimilars 98

Biosimilars Production FDA Drugs 98

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

NOVEMBER 9, 2021

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. drug channel will limit the impact of this impressive breakthrough. Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar.

Biosimilars 98

Biosimilars Production FDA Drugs 98

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Summer unofficially began over the weekend. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

Drug Channels

FEBRUARY 21, 2024

Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs , even as the government and manufacturers will prefer a low-list-price version. Just another IRA-inflicted hit for biosimilars? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars 98

Biosimilars Drugs Government Production 98

Drug Channels

OCTOBER 27, 2021

So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! It’s the biosimilar boom! Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 97

Biosimilars Hospitals Independent Pharmacies Pharmacy 97

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. d/b/a Drug Channels Institute. to 1:30 p.m.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

JUNE 27, 2021

As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing.

Biosimilars 52

Biosimilars Hospitals Pharmacy Vaccine 52

Drug Channels

JULY 27, 2021

In this issue: The top 10 stingiest hospitals Medicare Part B's savings from biosimilars What happened to hepatitis C drug costs and rebates? Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 52

Biosimilars Hospitals Drugs 52

Drug Channels

AUGUST 25, 2021

Time to pack away the bathing suit and get serious again—with these curated curiosities combed from the now-barren Drug Channels beach: OptumRx joins the PBM GPO game Pharmacy DIR fees hit $11 billion A terrific resource on state biosimilar laws Patient views on utilization management Plus, my social media success…from a (print) newspaper ad!

Biosimilars 83

Biosimilars Pharmacy Drugs Research 83

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Biosimilars 52

Biosimilars Specialty Pharmacies Pharmacy Hospitals 52

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

NOVEMBER 9, 2022

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

SEPTEMBER 28, 2021

Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Hospitals 81

Hospitals Biosimilars Pharmacy International 81